Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 43M | 35M | 32M | 28M | 29M |
| Gross Profit | 32M | 28M | 26M | 23M | 23M |
| Operating Income | 11M | 9M | 7M | 7M | 8M |
| EBITDA | 12M | 10M | 8M | 7M | 9M |
| Net Income | 9M | 7M | 6M | 5M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$9.90
+1.43% today
1Y Change
+16.80%
Window
Jun 26, 2025 → Jun 16, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioSyent Inc. (BIOYF) is a Healthcare stock with a market cap of $170.00M. The stock last traded around $9.90 and up 16.8% across the available one-year price window (Jun 26, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +22.8%, EPS growth of +25.0%, a dividend yield of 1.4%. What stands out right now is revenue +22.8%, EPS +25.0%, free cash flow +139.3% with operating margin 26.4% and ROIC 20.0%. The dividend is present but secondary, with a yield around 1.4%. Valuation is more restrained than many high-expectation growth names at P/E 18.2 and price/sales 3.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines BIOYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BIOYF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BIOYF Max Drawdown
-15.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BIOYF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$28.6M
+2.5% YoY
FY Net Income
$6.3M
+15.1% YoY
Free Cash Flow
$4.6M
+3.4% YoY
Revenue Growth
+22.8%
EPS Growth
+25.0%
Gross Margin
76.0%
Net Margin
20.9%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 43M | 35M | 32M | 28M | 29M |
| Gross Profit | 32M | 28M | 26M | 23M | 23M |
| Operating Income | 11M | 9M | 7M | 7M | 8M |
| EBITDA | 12M | 10M | 8M | 7M | 9M |
| Net Income | 9M | 7M | 6M | 5M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20M | 12M | 8M | 8M | 18M |
| Total Assets | 49M | 41M | 42M | 40M | 37M |
| Total Liabilities | 8M | 6M | 7M | 7M | 6M |
| Shareholder Equity | 41M | 35M | 35M | 33M | 32M |
| Total Debt | 840K | 1M | 1M | 1M | 2M |
| Net Debt | -19M | -11M | -7M | -6M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
-5.5% YoY
Capital Expenditures
93K
+82.1% YoY
Free Cash Flow
5M
+3.4% YoY
Key ratios
Gross Margin
76.0%
Operating Margin
26.4%
Net Margin
20.9%
ROE
23.3%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.